{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.6","value":"26.7"},{"groupId":"OG001","spread":"37.9","value":"25.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"PK parameters were calculated by standard non-compartmental analysis. T1/2 is the elimination half-life","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"},{"description":"Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)","id":"OG001","title":"LGG Cohort: Dabrafenib and Trametinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who received at least one dose of trametinib with an evaluable T1/2 PK parameter","reportingStatus":"POSTED","timeFrame":"Week 3 Day 1 pre-dose and 0.5, 1, 2, 3, 4, 6, 8 hours post-dose","title":"T1/2 for Trametinib","type":"SECONDARY","unitOfMeasure":"hour"}